Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors
摘要:
An increasing number of diseases have been linked to a dysfunctional peripheral serotonin system. Given that tryptophan hydroxylase 1 (TPH1) is the rate limiting enzyme in the biosynthesis off serotonin, it represents an attractive target to regulate peripheral serotonin. Following up to our first disclosure, we report a new chemotype of TPH1 inhibitors where-by the more common central planar heterocycle has been replaced with an open-chain, acyl guanidine surrogate. Through our work, we found that compounds of this nature provide highly potent TPH1 inhibitors with favorable physicochemical properties that were effective in reducing murine intestinal 5-HT in vivo. Furthermore, we obtained a high resolution (1.90 angstrom) X-ray structure crystal structure of one of these inhibitors (compound 51) that elucidated the active conformation along with revealing a dimeric form of TPH1 for the first time. (C) 2016 Elsevier Ltd. All rights reserved.
[EN] ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS<br/>[FR] ACYLGUANIDINES COMME INHIBITEURS DE LA TRYPTOPHAN HYDROXYLASE
申请人:KAROS PHARMACEUTICALS INC
公开号:WO2015089137A1
公开(公告)日:2015-06-18
The present invention is directed to acylguanidines which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPHl), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors
作者:Daniel R. Goldberg、Stéphane De Lombaert、Robert Aiello、Patricia Bourassa、Nicole Barucci、Qing Zhang、Vishwas Paralkar、Adam J. Stein、Jim Valentine、William Zavadoski
DOI:10.1016/j.bmcl.2016.04.057
日期:2016.6
An increasing number of diseases have been linked to a dysfunctional peripheral serotonin system. Given that tryptophan hydroxylase 1 (TPH1) is the rate limiting enzyme in the biosynthesis off serotonin, it represents an attractive target to regulate peripheral serotonin. Following up to our first disclosure, we report a new chemotype of TPH1 inhibitors where-by the more common central planar heterocycle has been replaced with an open-chain, acyl guanidine surrogate. Through our work, we found that compounds of this nature provide highly potent TPH1 inhibitors with favorable physicochemical properties that were effective in reducing murine intestinal 5-HT in vivo. Furthermore, we obtained a high resolution (1.90 angstrom) X-ray structure crystal structure of one of these inhibitors (compound 51) that elucidated the active conformation along with revealing a dimeric form of TPH1 for the first time. (C) 2016 Elsevier Ltd. All rights reserved.